Nasus Pharma Ltd（NSRX）財務資料NSRXNasus Pharma Ltd

In the context of the broader market, NSRX competes directly with industry leaders such as PTHS and EDSA. With a market capitalization of $33.14M, it holds a significant position in the sector. When comparing efficiency, NSRX's gross margin of N/A stands against PTHS's 70.18% and EDSA's N/A. Such benchmarking helps identify whether Nasus Pharma Ltd is trading at a premium or discount relative to its financial performance.

Nasus Pharma has reported increasing net losses, with a net loss of $5.9 million for 2025, compared to $1.5 million in 2024. However, the company has improved its cash position significantly, with cash and equivalents totaling $4.3 million as of December 31, 2025, up from $0.3 million the previous year.